एकालाब्रुटिनिब और सिमेटिडीन का इंटरैक्शन

• CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors.

• Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs).

Prevention or Management • Avoid co-administration of strong CYP3A inhibitors with CALQUENCE.

Effect of Other Drugs on CALQUENCE Strong CYP3A Inhibitors Clinical Effect • Co-administration of CALQUENCE with a strong CYP3A inhibitor (itraconazole) increased acalabrutinib plasma concentrations [see Clinical Pharmacology (12.3) ] .

Moderate CYP3A Inhibitors Clinical Effect • Co-administration of CALQUENCE with a moderate CYP3A inhibitor may increase acalabrutinib plasma concentrations [see Clinical Pharmacology (12.3) ].